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Available online 13 April 2016The knowledge of the biological mechanisms leading to the induction of skin sensitisation has favoured in recent
years the development of alternative non-animalmethods. During the formal validation process, results from the
Local LymphNode Assay (LLNA) are generally used as reference data to assess the predictive capacity of the non-
animal tests. This study reports an analysis of the variability of the LLNA for a set of chemicals for which multiple
studies are available and considers three hazard classiﬁcation schemes: POS/NEG, GHS/CLP and ECETOC. As the
type of vehicle used in a LLNA study is known to inﬂuence to some extent the results, two analyses were per-
formed: considering the solvent used to test the chemicals and without considering the solvent. The results
show that the number of discordant classiﬁcations increaseswhen a chemical is tested inmore than one solvent.
Moreover, it can be concluded that study results leading to classiﬁcation in the strongest classes (1A and EXT)
seem to be more reliable than those in the weakest classes. This study highlights the importance of considering
the variability of the reference data when evaluating non-animal tests.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Validation1. Introduction
The knowledge of the biological mechanisms leading to the induc-
tion of skin sensitisation has favoured in recent years the development
of in chemico and in vitro test methods targeting key events of the skin
sensitisation Adverse Outcome Pathway (AOP; OECD 2012). Three of
these methods, the Direct Peptide Reactivity Assay (DPRA), the
KeratinoSens™ and the human Cell Line Activation Test (h-CLAT)
underwent formal validation and independent peer-review (EURL
ECVAM 2013; EURL ECVAM 2014; EURL ECVAM, 2015a). The Organisa-
tion for Economic Co-operation and Development (OECD) adopted in
2015 the DPRA and the KeratinoSens™ as Test Guidelines (TG) 442C
and 442D respectively (OECD 2015a; OECD 2015b), and a draft TG for
the h-CLAT test method is in the ﬁnal stages of the OECD adoption pro-
cess.Within the TGs the validated testmethods are proposed to supportoil (4:1 by volume); DMF,
cing a stimulation index of 3;
(ECETOC classiﬁcation); IDR,
ssiﬁcation); NEG, negative; SI,
ethyl-2-(hydroxymethyl)-1,3-
. Fermi 2749, 21027 Ispra (VA),
. This is an open access article underthe discrimination between skin sensitisers and non-sensitisers for
the purpose of hazard classiﬁcation according to the United Nations
Globally Harmonized Systemof Classiﬁcation and Labelling of chemicals
(UN GHS; UN, 2015) and the European Union Regulation on Classiﬁca-
tion, Labelling and Packaging (EU CLP; European Commission, 2008).
Besides these methods, a number of other assays are under develop-
ment or evaluation (e.g. Johansson and Lindstedt, 2014; Reisinger
et al., 2015). It is a commonly held view that the inherent limitations
of the available methods, including the limited mechanistic coverage
of the biological events leading to the acquisition of skin sensitisation,
impede their use in isolation as full replacements of the currently used
animal tests. For this reason, it is envisaged that only a combination of
methods used in the context of Integrated Approaches to Testing and
Assessment (IATA) will be able in the short term to replace the usage
of animals for regulatory purposes. An IATA can be deﬁned as an ap-
proach based onmultiple information sources used for the hazard iden-
tiﬁcation, hazard characterisation and/or safety assessment of
chemicals. An IATA integrates and weights all relevant existing data,
and guides the targeted generation of new data, where required, to in-
form regulatory decision-making regarding potential hazard and/or
risk.
Progress has been made in recent years in the development of de-
ﬁned approaches to testing and assessment for skin sensitisation
based on a ﬁxed set of information sources, e.g. in silico, in chemicothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
GHS/CLP and ECETOC potency classiﬁcation based on EC3 values derived from the LLNA.
Potency class EC3 (%) cut-off values
GHS/CLP classiﬁcation
1A ≤2
1B N2 –
ECETOC classiﬁcation
Extreme b0.1
Strong ≥0.1 – b1
Moderate ≥1 – b10
Weak ≥10 – ≤100
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integration and interpretation of data from the various sources also in
a ﬁxed, deﬁned way. The OECD is currently working on the develop-
ment of guidance on how to report such deﬁned approaches proposed
to be used within IATA with speciﬁc emphasis on those developed in
the skin sensitisation area (Draft OECD Document — not yet publicly
available). As in the case of individual testmethods, deﬁned approaches
to testing and assessment are considered with respect to their accuracy
in correctly predicting the in vivo response.
Among the animal tests, the Local Lymph Node Assay (LLNA) is gen-
erally used as the gold standard against which the performance of alter-
native methods is compared (e.g. Piroird et al., 2015; Urbisch et al.,
2015). The LLNA provides quantitative information on sensitisation po-
tency expressed as an EC3 value (i.e. the concentration of test chemical
required to induce a 3-fold increase in lymph node cell proliferation)
allowing also the evaluation of concentration-response information
from in chemico and in vitro methods. During the formal validation of
non-animal testing methods, test chemicals for which the in vivo re-
sponse is less uncertain are selected, for example by selecting those
with LLNA positive or negative classiﬁcations that are consistent with
other in vivo responses (i.e. data from guinea-pig test or human data)
(Casati et al., 2009; EURL ECVAM, 2012; EURL ECVAM, 2015b). Thus,
the variability of the LLNA data (or other in vivo reference data) and
its impact on the assessment of alternative methods are usually not ex-
plicitly addressed in validation activities. The emphasis is rather on es-
tablishing a balanced validation set comprising substances with
different physicochemical properties, sensitisation potency, reaction
mechanisms and diverse structures. However, when evaluating the pre-
dictive capacity of the deﬁned approaches, generally many more
chemicals are used and therefore the criteria used in the chemicals se-
lection for the validation study are no longer feasible to use. Thus,
therewill certainly be chemicalswith dubious in vivo data in this partic-
ular case and therefore the uncertainty associated with the reference
data increases.
Knowledge of the variability of the in vivo reference method would
allow for a more quantitative assessment of non-animal methods and
deﬁned approaches to testing and assessment. In fact, several toxicolog-
ical investigations have shown the value of conducting an analysis of
reference method variability (Adriaens et al., 2014; Hoffmann, 2015;
Barroso et al., 2016).
This study reports a statistical analysis of published available LLNA
data in order to characterise the inherent variability of the LLNA for
both hazard assessment (sensitisers versus non-sensitisers) and sensiti-
sation potency categorisation. Since the type of vehicle used in a LLNA
study is known to inﬂuence to some extent the EC3 value (Basketter
et al., 2001; Jowsey et al., 2008; Anderson et al., 2011) our analysis
was ﬁrst performed by considering chemicals that have been tested
more than once with the same vehicle. This ﬁrst analysis (referred to
hereafter as “solvent considered”) allowed us to characterise the biolog-
ical component of LLNA assay variability, since the contribution of the
vehicle was removed. However, in practice, whenmultiple LLNA results
are available for a given chemical, the studies have often been per-
formed with different vehicles making it difﬁcult to identify which
study results are more relevant for the purpose of evaluating non-
animal methods. For this reason, the analysis of LLNA variability was
also performed by considering all studies for a given chemical irrespec-
tive of the vehicle used. This second analysis (referred to hereafter as
“solvent not considered”) allowed us to characterise the overall (biolog-
ical and vehicle-related) variability of the LLNA.
2. Materials and methods
2.1. Data sources
The evaluation of the LLNA variability was performed using the Na-
tional Toxicology Program Interagency Centre for the Evaluation ofAlternative Toxicological Methods (NICEATM) LLNA Database
(niceatm-llnadatabase-23dec2013.xls), which is publicly available at:
http://ntp.niehs.nih.gov/results/dbsearch/index.html#NICEATM-LLNA-
Database. This database pools data from published and unpublished
data sources with permission and comprises 669 chemicals and a total
of 1060 entries (i.e. 1060 LLNA studies). Each chemical is identiﬁed by
name, CAS number, molecularweight and chemical class. Each entry re-
ports the details of one LLNA study: the concentrations tested (%), the
stimulation index (SI) for each concentration, the EC3 value (%) for pos-
itive chemicals (or NC for negative results), the LLNA result (positive—
POS or negative — NEG) and the original reference. For some positive
chemicals, the dose-response observed in the experiment was insufﬁ-
cient to calculate an EC3 value; in such cases the abbreviation IDR (In-
sufﬁcient Dose Response) is reported instead of the EC3 value.
For the purpose of this study, the NICEATM LLNA database was sup-
plemented with LLNA data retrieved from: 1) Basketter et al. (2014):
this paper reports EC3 values for 105 chemicals, but the solvent used
in each study is not speciﬁed in the publication; 2) Piroird et al.
(2015): this paper includes a database of 175 chemicals, reporting EC3
values for each chemical; 3) Urbisch et al. (2015): this paper presents
a database of 213 chemicals, reporting the EC3 values for each chemical
and the original references; 4) the QSAR Toolbox (available at: http://
www.qsartoolbox.org/). From these three last data sources, and when
it was possible, the solvent used to test the chemical was retrieved
from the original reference.
All the identiﬁed LLNA study duplicates were removed for the pur-
pose of the analysis.2.2. Analysis of the data
2.2.1. Selection of chemicals
For the analysis of variability considering the potential solvent effect
(“solvent considered”), studies were grouped on the basis of the CAS
number of the tested chemical and the solvent used for testing.
For the analysis of variability without taking into consideration the
solvent effect (“solvent not considered”), studies were grouped accord-
ing to the CAS number of the tested chemical, regardless of the solvent
used for testing.
In both cases, all the chemicals with at least two studies were re-
trieved from the ﬁnal database and used for the analysis.2.2.2. Classiﬁcation of LLNA studies
For the purpose of the analysis, LLNA studies were classiﬁed as pos-
itive/negative (POS/NEG) according to the classiﬁcation criteria in the
OECD TG 429 (OECD, 2009), where an LLNA study is considered as pos-
itive if the SI at any tested dose is ≥3. In addition, for substances identi-
ﬁed as positive in the LLNA, the GHS/CLP hazard sub-categorisation
criteria for distinguishing between Category 1A (strong skin sensitisers
and substances showing high potency in animals) and Category 1B
(other sensitisers and substances showing low to moderate potency in
animals)were applied (Table 1).Moreover, the four potency categories:
weak (WEAK), moderate (MOD), strong (STRONG) and extreme (EXT),
Table 2
GHS/CLP classiﬁcation scheme: examples of grouping and distribution of normalised studies.
Chemicals
(solvent)
Number of
studies
with NEG result
Number of studies
with
Category 1B result
Number of studies
with
Category 1A result
Assignment
to groupsa
Study distribution
according to classes
Distribution of the normalised studies
in the different classesb,c
Glycerol (DMF) 2 0 0 NEG group 2/2 studies→ NEG
0/2 studies→ 1B
0/2 studies→ 1A
NEG group: NEG = 1/1B = 0/1A = 0
Atrazine (ACE) 2 2 0 NEG & 1B groups 2/4 studies→ NEG
2/4 studies→ 1B
0/4 studies→ 1A
NEG group: NEG = 0.5/1B = 0.5/1A = 0
1B group: NEG = 0.5/1B = 0.5/1A = 0
Benzocaine
(DMF)
5 1 1 NEG, 1B & 1A
groups
5/7 studies→ NEG
1/7 studies→ 1B
1/7 studies→ 1A
NEG group: NEG= 0.72/1B = 0.14/1A = 0.14
1B group: NEG = 0.72/1B = 0.14/1A = 0.14
1A group: NEG = 0.72/1B = 0.14/1A = 0.14
a Chemicals with discordant studies are represented in more than one group.
b In the analyses, the ﬁnal weight of each chemical in each group to which it is assigned is always 1, being equal to the sum of the scores of the normalised studies.
c The text in bold indicates the proportion of classiﬁcations matching the group designation (e.g., the proportion of 1B classiﬁcations in the 1B group).
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Chemicals (ECETOC, 2003) were considered (Table 1).
For the purpose of the analysis, each chemical was assigned to a
group (i.e POS or NEG for POS/NEG classiﬁcation scheme; NEG, 1B or
1A for GHS/CLP classiﬁcation scheme; NEG, WEAK, MOD, STRONG or
EXT for ECETOC classiﬁcation scheme) on the basis of having at least
one study resulting in a classiﬁcation matching that group. Chemicals
with discordant studies are therefore represented in more than one
group. Then, within each group, the multiple studies available for each
chemical were distributed in the corresponding relevant classiﬁcation/
potency classes (Table 2). Since the chemicals analysed have a variable
number of repeat studies available (ranging from 2 to 40 for the study
“solvent considered” and from 2 to 46 for the study “solvent not consid-
ered”), each study was normalised to the total number of studies avail-
able for that chemical, i.e. the number of studies assigned to a speciﬁc
class for a given chemical was divided by the total number of studies
available for that chemical (Table 2). In this way, each chemical contrib-
utes with a ﬁnal weight of 1 in all analyses performed.
Table 2 illustrates how the LLNA studies for three chemicals glycerol
(2 studies), atrazine (4 studies) and benzocaine (7 studies) were
assigned to the different groups and classes on the basis of the classiﬁca-
tion criteria described in Table 1 and the normalisation of the studies
described above.2.2.3. Number of chemicals used for the analysis
The LLNA database used for the analysis reports results for 87
chemicals (400 studies) that were eligible for the “solvent considered”
analysis and for 93 chemicals (518 studies) that were eligible for the
“solvent not considered” analysis. Two reasons explain the difference
in numbers: 1) some chemicals had multiple studies but only a single
study for a given solvent; this type of studywasnot included in the anal-
ysis “solvent considered” but was included in the analysis “solvent not
considered”; and 2) the database was supplemented with chemicals
for which the solvent used was not reported in the original reference,
these chemicals were included only in the “solvent not considered”
analysis.
Among the 87 chemicals used for the “solvent considered” analysis,
85 were eligible for the GHS/CLP and the ECETOC classiﬁcations. Two
chemicals were removed from the GHS/CLP and ECETOC analyses
since only one study qualiﬁed — in the second study the dose-
response was not sufﬁcient to derive an EC3 value andwas therefore la-
belled as IDR. Nevertheless, the studies labelled as IDRwere included in
the POS/NEG analysis, being attributed to the POS class. For the “solvent
not considered” analysis, among the 93 chemicals with multiple studyresults, 87 were eligible for the GHS/CLP and ECETOC analyses. Six
chemicals were removed for the same reason explained above.
3. Results
3.1. Distribution of chemicals with concordant and discordant results
First, data were analysed on the basis of whether the repeat studies
available for each chemical, and conducted using the same solvent,
yielded concordant or discordant results for the classiﬁcation scheme
considered (Fig. 1). For the three different classiﬁcations schemes con-
sidered in our analysis, approximately 10% of the chemicals have con-
cordant negative studies. As expected, the number of chemicals with
discordant studies increases with the number of classes considered:
22% for the POS/NEG classiﬁcation (2 classes), 38% for the GHS/CLP clas-
siﬁcation (3 classes) and 52% for ECETOC classiﬁcation (5 classes).
A similar evaluationwas performedwithout considering the solvent
used in the studies available for each chemical (Fig. 2). In this case, only
around5%of the chemicals show concordant negative studies (irrespec-
tive of the classiﬁcation scheme). As before, the percentage of chemicals
with discordant study results increases with the number of classes con-
sidered: 32% for POS/NEG, 51% for the GHS/CLP classiﬁcation and 61%
for the ECETOC classiﬁcation.
3.2. LLNA EC3 value variability
The EC3 values (expressed as % concentration) reported for each
study were used to analyse the inherent variability of the LLNA. The
mean of the logarithmically (decimal) transformed EC3 values available
for each chemical and the standard deviation (SD) were plotted on a
graph with the chemicals ordered by increasing EC3 mean. Studies for
which an EC3 value was not available in the database (i.e. NEG and
IDR) were also included on the graph even though they did not contrib-
ute to the calculation of the mean EC3 and SD. Figs. 3 and 4 show the
variability of the EC3 values when the solvent effect is considered, and
not considered, respectively. The chemicals used for both analyses pro-
vide a good coverage of skin sensitisation potency and distribution in all
the classes of the GHS/CLP and ECETOC classiﬁcation schemes. Figs. 3
and 4 show that the variability of the LLNA is more or less consistent
throughout the sensitising potency scale and doesn't seem to correlate
with a speciﬁc potency class.
Concerning the “solvent considered” analysis (Fig. 3), the highest
variability in EC3 values (SD of Log EC3 values N0.5) was observed, in
decreasing order of variability, for oxalic acid when tested in
dimethylformamide (DMF); tetramethylthiuram disulphide tested in
Fig. 1. Distribution of chemicals with concordant/discordant study results in the “solvent
considered” analysis. A: POS/NEG classiﬁcation; B: GHS/CLP classiﬁcation; chemicals
with concordant positive studies were assigned to the corresponding sub-category 1B or
1A; C: ECETOC classiﬁcation; chemicals with concordant positive studies were assigned
to the corresponding potency class WEAK, MOD, STRONG or EXT.
Fig. 2. Distribution of chemicals with concordant/discordant study results in the “solvent
not considered” analysis. A: POS/NEG classiﬁcation; B: GHS/CLP classiﬁcation; chemicals
with concordant positive studies were assigned to the corresponding sub-category 1B or
1A; C: ECETOC classiﬁcation; chemicals with concordant positive studies were assigned
to the corresponding potency class WEAK, MOD, STRONG or EXT.
223C. Dumont et al. / Toxicology in Vitro 34 (2016) 220–2284:1 acetone:olive oil (AOO); trimellitic anhydride tested in AOO; phenyl
benzoate tested in AOO; ethyl-2-(hydroxymethyl)-1,3-propanediol
triacrylate (TMPTA) tested in acetone (ACE); 4-phenylenediamine test-
ed in AOO; 1,2-benzisothiazolin-3-one tested in DMF; jasmine absolute
tested in 1:3 ethanol/diethylphthalate (ETOH/DEP); aniline tested in
AOO; and benzoyl peroxide tested in ACE. As a result of the highly var-
iable LLNA results for these 10 chemicals no speciﬁc potency class can be
assigned with 100% conﬁdence.
Concerning the “solvent not considered” analysis (Fig. 4), thehighest
variability in EC3 values (SD of Log EC3 values N0.5) was observed, in
decreasing order of variability, for oxalic acid; trimellitic anhydride;
tetramethylthiuram disulphide; benzoyl peroxide;
diphenylcyclopropenone; TMPTA; formaldehyde; glutaraldehyde; 4-
phenylenediamine; 1,2-benzisothiazolin-3-one; phenyl benzoate; jas-
mine absolute; and 2,4-dinitrobenzene sulfonic acid. As a result of the
highly variable LLNA results for these 13 chemicals, no speciﬁc potency
class can be assigned with 100% conﬁdence.
Finally, it is worth noting that LLNA negative results were obtained
even for chemicals showing extreme or strong sensitising results
(EC3 ≤ 2%; Log EC3 ≤ 0.3) in repeat studies both in the “solvent consid-
ered” analysis shown in Fig. 3 (e.g. cobalt chloride tested in DMSO,
tetramethylthiuram disulphide tested in AOO, 1,4-dihydroquinone test-
ed in acetone/saline (1:1)) and in the “solvent not considered” analysis
shown in Fig. 4 (e.g. benzalkonium chloride, potassiumdichromate, 1,4-dihydroquinone). Also for these chemicals it may be difﬁcult to assign a
potency class with 100% conﬁdence.
3.3. Distribution of LLNA studies in different classes
The analysis of the distribution of LLNA studies is presented in
Table 3. To avoid bias in the analysis due to the different numbers of re-
peat studies available for each chemical (n = 2 to 40 for the “solvent
considered” analysis and n = 2 to 46 for the “solvent not considered”
analysis), the studies were normalised as described in the Materials
and methods section. The percentage of studies in each class was then
calculated by dividing the sum of the scores of the normalised studies
assigned to that class by the total number of chemicals in the group.
It is worth noting that irrespective of the classiﬁcation scheme the
number of chemicals with negative LLNA studies is almost the same,
i.e. 28 for the “solvent considered” analysis and 35 for the “solvent not
considered” analysis. Among these chemicals, 19 out of 28 (68%) and
30 out of 35 (86%) in the “solvent considered” and “solvent not consid-
ered” analyses, respectively, have studies with discordant results.
3.3.1. POS/NEG classiﬁcation scheme
The “solvent considered” analysis shows that 19 out of 78 (24%)
chemicals in the POS group give discordant study results, which is
Fig. 3.Analysis of the inherent variability of the LLNA considering the solvent. Data are presented asMean±SDof log-transformedEC3 values (n=87) for chemicals ordered by increasing
mean EC3 value and considering the solvent used to test the chemical (“solvent considered”). The number associatedwith each error bar reports the number of experiments with an EC3
value and used for the calculation of themean and SD. The symbol × and♦ respectively indicate that at least one IDR or at least one NEG result is available for that chemical in the database.
The numbers associatedwith these symbols represent thenumber of IDR orNEG studies. The grey dotted line represents theGHS/CLP classiﬁcation cut-off; the black dotted lines represent
the ECETOC classiﬁcation cut-offs.
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when considering all chemicals, in the NEG group only 65% of the stud-
ies classify the chemical as negativewhereas in the POS group 88%of the
studies classify the chemicals as positive (Table 3). In other words, the
probability that a negative study, if repeated, would lead to a positive
classiﬁcation is as high as 35%, compared to a probability of only 12%
for obtaining a negative result when repeating a positive study. There
is therefore considerably higher certainty in a POS result obtained
with a single LLNA study than in a single study with a NEG result.
When the analysis is performedwithout considering the solvent, the
proportion of chemicals with discordant study results increases for both
groups: 30 out of 35 (86%) for the NEG group and 30 out of 88 (34%) for
the POS group (Table 3). Also in this case the results for all chemicals
demonstrate that there is higher certainty in a POS result obtained
with a single LLNA study (85% probability of obtaining again a positive
result in a repeat study) than in a single study with a NEG result (51%
probability of obtaining again a negative result in a repeat study).
3.3.2. GHS/CLP classiﬁcation scheme
When considering GHS/CLP, for the 19 chemicals with discordant
studies assigned to the NEG group in the “solvent considered” analysis,
34% and 16% of the studies classify the chemicals as Category 1B and
Category 1A, respectively, with the remaining 50% being NEG.Considering all the chemicals, 66% of the studies identify the chemicals
as NEG, 23% as Category 1B, and 11% as Category 1A. As expected, the
percentage of studies classifying the chemicals as NEG decreases be-
tween the analysis for all chemicals and the one for only the chemicals
with discordant studies, while increasing for Category 1B and remaining
roughly the same for Category 1A (Table 3). Similarly, the percentage of
studies identifying the chemicals as NEG decreases when the analysis is
performed not considering the solvent (Table 3).
In the 1B group when considering the solvent, 28 out of 50 (56%)
chemicals have studies with discordant results. Less than 50% of those
studies classify the chemicals “correctly” as Category 1B (43%), with
the rest identifying them evenly as NEG (29%) or Category 1A (28%).
Without considering the solvent, the proportion of chemicals with dis-
cordant studies increases slightly (39 out of 65; 60%). Similarly to
what observed in the analysis performed considering the solvent, 50%
of the experiments classify the chemicals as Category 1B (46%), with a
roughly equal distribution of the remaining studies between a NEG
(30%) and a Category 1A (24%) outcome. Finally, taking into account
the 50 chemicals in the 1B group (including those with discordant as
well as those with concordant studies), 68% of the studies identiﬁed
the chemicals as Category 1B (in both the “solvent considered” and “sol-
vent not considered” analyses), with the rest identifying them evenly as
NEG (16–18%) or Category 1A (14–16%) (Table 3).
Fig. 4. Analysis of the inherent variability of the LLNA not considering the solvent. Data are presented as Mean ± SD of log-transformed EC3 values (n = 93) for chemicals ordered by
increasing mean EC3 value and without considering the solvent used to test the chemical (“solvent not considered”). The number associated with each error bar reports the number of
experiments with an EC3 value and used for the calculation of the mean and SD. The symbol × and ♦ respectively indicate that at least one IDR or at least one NEG result is available
for that chemical in the database. The numbers associated with these symbols represent the number of IDR or NEG studies. The grey dotted line represents the GHS/CLP classiﬁcation
cut-off; the black dotted lines represent the ECETOC classiﬁcation cut-offs.
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ered” analysis have studieswith discordant results, with this proportion
increasing (24 out of 36 chemicals; 67%)when the solventwas not con-
sidered. In both analyses, about half of those studies classiﬁed the
chemicals as Category 1A (53–55%), while 32–34% identiﬁed the same
chemicals as Category 1B and 13% as being NEG. The study distribution
for all chemicals shows that 79% (“solvent considered”) and 69% (“sol-
vent not considered”) of the studies classify the chemicals as Category
1A. Accordingly, the proportions of Category 1B (15–23%) and NEG
(6–8%) studies decrease to nearly half of what is observed for only the
chemicals with discordant studies (Table 3).
3.3.3. ECETOC classiﬁcation scheme
Focusing on the discordant chemicals, it can be observed that only
50% of the studies identify the chemicals as NEG. The other half of the
studies assigns the chemicals to the WEAK (17%), MOD (23%),
STRONG (8%) or EXT (2%) classes (Table 3). When looking at the distri-
bution of the studies for all the chemicals assigned to the NEG group in
the “solvent considered” analysis, 34% of the studies identify the
chemicals as skin sensitisers (12% WEAK, 16% MOD, 5% STRONG and
1% EXT).When the solvent is not considered, the pattern of study distri-
bution for all chemicals and for discordant chemicals remains the same
as when solvents are considered, with the percentage of studies identi-
fying the chemicals as NEG decreasing and the proportions of all other
classes increasing.In the WEAK group, 22 out of 29 (76%) or 26 out of 37 (70%)
chemicals have discordant studies in the “solvent considered” and “sol-
vent not considered” analyses, respectively. Less than half of the discor-
dant studies classify the chemicals as WEAK (45–47%), with the
majority of the remaining studies identifying the chemicals with only
one class difference (15–24% NEG and 27–36% MOD). Considering the
study distribution for all chemicals in the WEAK group, about 40% of
the studies identify the chemicals as being other than WEAK (in both
the “solvent considered” and “solvent not considered” analyses), with
the majority of these studies again being either NEG (11–17%) or
MOD (19–28%). The pattern of distribution of the studies does not
vary much between the “solvent considered” and the “solvent not con-
sidered” analyses.
In theMODgroup, 32 out of 40 (80%) or 36 out of 46 (78%) chemicals
have discordant studies in the “solvent considered” and “solvent not
considered” analyses, respectively. Like in the WEAK group, less than
half of the discordant studies classify the chemicals as MOD (45–47%)
but, in this case, the majority of the remaining studies identify the
chemicals as either WEAK (19–24%) or NEG (18–19%), i.e. with up to
two classes difference. Considering the study distribution for all
chemicals in the MOD group, 57% of the studies identify the chemicals
as being MOD (in both the “solvent considered” and “solvent not con-
sidered” analyses), with the majority of the remaining studies again
identifying the chemicals with up to two classes difference (15% NEG
and 15–19% WEAK). The pattern of distribution of the studies also
Table 3
Distribution of LLNA studies according to the three classiﬁcation schemes. Theﬁrst values correspond to the “solvent considered” analysis; values in brackets correspond to the “solvent not
considered” analysis.
POS/NEG classiﬁcation
Total no of chemicalsa No of chemicals with discordant studies Study distribution for
chemicals with discordant
studies (%)
Study distribution for all
chemicals (%)
NEG class POS class NEG class POS class
NEG group 28 (35) 19 (30) 49 (43) 51 (57) 65 (51) 35 (49)
POS group 78 (88) 19 (30) 12 (15) 88 (85)
GHS/CLP classiﬁcation
Total no of chemicalsa No of chemicals with discordant studies Study distribution for chemicals with
discordant studies (%)
Study distribution for all chemicals
(%)
NEG class 1B class 1A class NEG class 1B class 1A class
NEG group 28 (35) 19 (30) 50 (44) 34 (41) 16 (15) 66 (52) 23 (35) 11 (13)
1B group 50 (65) 28 (39) 29 (30) 43 (46) 28 (24) 16 (18) 68 (68) 16 (14)
1A group 41 (36) 19 (24) 13 (13) 32 (34) 55 (53) 6 (8) 15 (23) 79 (69)
ECETOC classiﬁcation
Total no of
chemicalsa
No of chemicals with
discordant studies
Study distribution chemicals with discordant
results (%)
Study distribution for all chemicals (%)
NEG
class
WEAK
class
MOD
class
STRONG
class
EXT
class
NEG
class
WEAK
class
MOD
class
STRONG
class
EXT
class
NEG group 28 (35) 19 (30) 50 (44) 17 (20) 23 (24) 8 (9) 2 (3) 66 (52) 12 (17) 16 (20) 5 (8) 1 (3)
WEAK group 29 (37) 22 (26) 15 (24) 47 (45) 36 (27) 0 (3) 2 (1) 11 (17) 60 (61) 28 (19) 0 (2) 1 (1)
MOD group 40 (46) 32 (36) 18 (19) 24 (19) 47 (45) 9 (13) 2 (4) 15 (15) 19 (15) 57 (57) 7 (10) 2 (3)
STRONG group 20 (19) 13 (18) 6 (7) 0 (2) 27 (30) 45 (41) 22 (20) 4 (6) 0 (2) 17 (29) 64 (44) 15 (19)
EXT group 17 (16) 7 (9) 1 (8) 5 (4) 6 (8) 42 (31) 46 (49) 1 (4) 2 (2) 2 (5) 17 (18) 78 (71)
a The number of chemicals in each group (shown in the second column) is determined on the basis of the number of chemicals in the database having at least one study resulting in a
classiﬁcation matching that group. Consequently, chemicals with discordant studies are represented in more than one group (see explanatory Table 2).
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not considered” analyses.
In the STRONG group, 13 out of 20 (65%) or 18 out of 19 (95%)
chemicals have discordant studies in the “solvent considered” and “sol-
vent not considered” analyses, respectively. Less than half of these dis-
cordant studies classify the chemicals as STRONG (41–45%), with the
majority of the remaining studies identifying the chemicals with only
one class difference (27–30% MOD and 20–22% EXT). Six to 7% of the
studies give a NEG outcome. Considering the study distribution for all
chemicals in the STRONG group, 64% or 44% of the studies identify the
chemicals as STRONG in the “solvent considered” and “solvent not con-
sidered” analyses, respectively. Again, the majority of the remaining
studies were identiﬁed with up to one class difference, i.e. either MOD
(17–29%) or EXT (15–19%). For the STRONG group, the study distribu-
tion varies between the “solvent considered” and the “solvent not con-
sidered” analyses when considering all chemicals (i.e., a considerably
lower percentage of STRONG studies in the “solvent not considered”
analysis), but not when considering only the discordant chemicals.
This is because only 1 chemical out of 19 has concordant studies if the
solvent is not considered versus 7 out 20 if the solvent is considered
(Table 3).
Finally, in the EXT group 7 out of 17 (41%) or 9 out of 16 (56%)
chemicals have discordant studies in the “solvent considered” and “sol-
vent not considered” analyses, respectively. About half of the discordant
studies classify the chemicals as EXT (46–49%), with the majority of the
remaining studies identifying the chemicals as STRONG (31–42%). Con-
sidering the study distribution for all chemicals in the EXT group, 71–
78% of the studies identify the chemicals as EXT with most of the re-
maining studies identifying the chemicals as STRONG (17–18%). Impor-
tantly, even in this EXT group, 1–4% of the studies give a NEG result
(Table 3).4. Discussion
The potential of a chemical to induce allergic contact hypersensitiv-
ity is an integral part of hazard assessment in the regulatory context. In
recent years, the LLNA has become the preferred method for skin sensi-
tisation because of animal welfare beneﬁts (compared with other ani-
mal models) and because it provides dose-response information from
which the relative sensitisation potency of a chemical can be derived
and used for safety assessment. However, important progress has
been made in the development of non-animal methods for skin sensiti-
sation testing due to the good understanding of the chemical and bio-
logical basis of this toxicological effect, as documented in the Adverse
Outcome Pathway (AOP) for skin sensitisation (OECD, 2012). Some of
these methods have recently been adopted by the OECD (OECD,
2015a; OECD, 2015b), and another one (h-CLAT) is at the ﬁnal stage in
the adoption process. Other methods are currently undergoing evalua-
tion in ring-trials (e.g. Gibbs et al., 2013; Johansson et al., 2014;
Cottrez et al., 2015; Ramirez et al., 2016). The available test methods
are measuring speciﬁc mechanisms of the skin sensitisation pathway
and as such, they are not generally proposed as stand-alone full replace-
ment methods. Activities are under way to understand how these
methods can be used in deﬁned approaches in the context of IATA in
order to replace animal testing for both hazard and risk assessment pur-
poses (e.g. Bauch et al., 2012; Jaworska et al., 2013; Nukada et al., 2013;
Maxwell et al., 2014; van der Veen et al., 2014; Hirota et al., 2015;
Jaworska et al., 2015; Natsch et al., 2015; Urbisch et al., 2015;
Takenouchi et al., 2015; Asturiol et al., submitted for publication).
Although the available methods represent individual pieces of the
puzzle, their predictive power has generally been evaluated in terms
of prediction of in vivo responses due to the lack of reference data for
the key events they are in fact measuring. LLNA data are predominantly
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and/or deﬁned approaches. During formal validation studies, attention
is paid to select chemicals for which the reference in vivo data are rela-
tively certain with regard to their skin sensitisation potential or lack
thereof (Casati et al., 2009; EURL ECVAM, 2013; EURL ECVAM 2014;
EURL ECVAM 2015a) to accurately judge the performance of the non-
animal methods under evaluation. The variability of the reference data
is rarely taken explicitly into account. However, many more chemicals
are generally used to evaluate the predictive capacity of deﬁned ap-
proaches to testing and assessment. In this case, the inclusion of test
chemicalswithmore uncertain reference data can no longer be avoided,
and the overall uncertainty associatedwith the reference data obviously
increases. It is therefore important to understand how reliable the refer-
ence data are, not only for judging non-animal methods/approaches
providing information on the potential skin sensitisation hazard but
also for methods/approaches aiming at potency prediction.
None of the animal and non-animal toxicity tests is perfect, and this
includes the LLNA whose strengths and limitations have been exten-
sively described in the scientiﬁc literature (Basketter et al., 2002;
Jowsey et al., 2008; Anderson et al., 2011). It is therefore important to
keep in mind the limitations of the reference data when using them
for assessing the performance of new test methods and of their combi-
nations in deﬁned approaches to testing and assessment, which cannot
be expected to be more accurate in predicting the reference data than
the reference method is predictive of itself (i.e. the reproducibility of
the reference method).
The objective of the study presented in this paper is to provide a pic-
ture of the variability of the LLNA for a set of chemicals for whichmulti-
ple studies are available. The LLNA variability analysis was performed
taking into consideration three classiﬁcation schemes: the positive/neg-
ative classiﬁcation (POS/NEG), the GHS/CLP classiﬁcation which
subcategorises sensitisers in subcategories 1A (strong sensitisers) and
1B (others than strong sensitisers), and the ECETOC classiﬁcation with
four potency classes (WEAK, MODERATE, STRONG and EXTREME).
In the LLNA, the vehicle used to solubilise the test chemicals is
known to have an impact on the relative potency (i.e. the EC3
value) of skin sensitising chemicals (Basketter et al., 2001; Jowsey
et al., 2008; Anderson et al., 2011; Hoffmann, 2015). Therefore, the
analysis was conducted by considering LLNA studies performed with
the same vehicle. In practice, in the presence of multiple LLNA studies
performed with different vehicles for the same chemical, it is difﬁcult
to select which studies are more relevant for the purpose of evaluating
non-animal methods. For this reason, the analysis of LLNA variability
was also performed without taking into consideration the solvent
used.
In a recent analysis published by Hoffmann (2015) the variability of
the LLNA assay was analysed using data reported in the NICEATM data-
base. The ECETOC classiﬁcation accounting for 5 potency classeswas the
one considered for the purpose of the study and the chemicals were
assigned to a potency class on the basis of the median EC3 values. Our
analysis is based on a different approach since it focused on the distribu-
tion of individual LLNA study results. The analysis was performed not
only for the ECETOC classiﬁcation scheme but also for the dichotomous
POS/NEG and the GHS/CLP classiﬁcation schemes. Our work therefore
complements the analysis performed by Hoffmann (2015).
The number of chemicals with discordant study results increases
with the number of classes considered. This number also increases
when the solvent effect is not taken into account (Figs. 1 and 2).
For example, for the dichotomous hazard classiﬁcation scheme
(POS/NEG) and when the solvent is considered, 22% of the chemicals
have discordant study results. When the solvent is not taken into
account, the percentage of chemicals with discordant studies in-
creases to 32%.
Considering the POS/NEG classiﬁcation scheme, LLNA studies
resulting in negative classiﬁcations tend to be less reliable than studies
with positive classiﬁcations. When considering the solvent, there is a35% chance that studies with negative results would lead to a positive
result if repeated. When the solvent is not considered the probability
of obtaining discordant results between LLNA studies increases to 50%.
The analysis of the LLNA studies distribution for the different clas-
siﬁcation schemes (Table 3) shows that the POS, 1A and EXT groups
have a lower percentage of chemicals with discordant studies than
other groups. In fact, with the exception of these three groups, this
proportion is always above 50%. Considering the “study distribution
for all chemicals”, the highest concordance is also observed for the
positive and strongest potency groups: POS (85–88%), 1A (69–79%)
and EXT (71–78%). For the other groups, the percentage of studies
classifying the chemicals to the same class is on average 64% for the
“solvent considered” analysis and 55% for the “solvent not considered”
analysis.
For the GHS/CLP classiﬁcation scheme and considering the NEG and
the 1A groups, the majority of the discordant studies were assigned to
the adjacent class 1B (Table 3). In the intermediate group 1B, an equal
proportion of the studies assigns the chemicals as NEG or 1A. For the
ECETOC classiﬁcation scheme, considering the NEG group, the results
show that most of the discordant studies were almost evenly assigned
to theMOD andWEAK classes. In theWEAK and EXT groups, the discor-
dant studies are mostly in the adjacent classes (MOD and STRONG, re-
spectively). The MOD group on the other hand shows that most of the
discordant studies were evenly distributed in the less severe WEAK
and NEG potency classes. Finally, the discordant results of the STRONG
group show an almost equal distribution between the two adjacent
classes of lower (MOD) and higher (EXT) potency. On the basis of this
analysis it is difﬁcult to identify a clear pattern for the distribution of
the discordant studies leading to a less or more severe classiﬁcation.
Of note is also the fact that even in the EXT group, 1 to 4% of the studies
gave a NEG result.
A second analysis was performed without considering the solvent
usedwhen testing the chemicals. Except for theWEAK andMODgroups
in the ECETOC classiﬁcation scheme and the 1B group in the GHS/CLP
classiﬁcation scheme, by not considering the solvent the proportion of
discordant studies increases. The highest proportion of discordant stud-
ies is for the NEG class for all three classiﬁcation schemes, the 1A class
for GHS/CLP, and the STRONG class for ECETOC. If only the discordant
chemicals are considered, the pattern of distribution is almost the
same as when the solvent is considered.
This study highlights the importance of considering the variability
of the LLNA when this assay is used as the standard against which to
compare the performance of alternative methods. Considering the
POS/NEG classiﬁcation scheme, LLNA studies resulting in negative
classiﬁcations tend to be less reliable than studies with positive classi-
ﬁcations. When potency classiﬁcation is considered (i.e. GHS/CLP and
ECETOC) study results leading to classiﬁcations in the strongest poten-
cy classes (1A and EXT) seem to be more reliable than those in the
weakest classes. As already observed by Hoffmann (2015), studies
with discordant classiﬁcations mainly classify the chemical in an adja-
cent class, but it does not appear possible to draw general conclusions
on whether such studies lead to a more severe or less severe
classiﬁcation.
Considering the current discussion at regulatory level on the accep-
tance of results from in vitro methods and their use within deﬁned ap-
proaches, it would be important, for a given regulatory application, to
discuss and agree on the level of accuracy required for acceptance of de-
ﬁned approaches based on the use of non-animal data. The deﬁnition of
such a level should be informed by the uncertainty associated with the
reference data. In the case of non-animal methods for skin sensitisation,
acceptable levels of accuracy for different classiﬁcation schemes can be
derived from the results presented in Table 3. For example, a level of ac-
curacy for identifyingNEG, 1B and 1A chemicals of 70%, 70% and 80%, re-
spectively, would be comparable to the performance of the LLNA based
on our most conservative analysis (i.e. best LLNA performance) con-
ducted by considering the solvent.
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